Investigating the theragnostic potential of I-caerin peptide in thyroid cancer.

Objective: Caerin is a new peptide with tumour toxicity and its uptake by tumour cells is independent of the sodium iodide symporter (NIS). Thyroid cancer is the most common cancers of endocrine malignancy. Radioiodine (I)-refractory thyroid cancer is the most lethal subtype of the thyroid cancers and remains a clinical challenge.